Combining specific pathway inhibitors with immune therapies, such as PD-1/PD-L1 blockers, can overcome pancreatic cancer’s immune evasion mechanisms, improving treatment outcomes (75, 76). Here, CD274 is linked to familial pancreatic carcinoma.